Note: Unnecessary use of -X or --request, POST is already inferred.
  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current
                                 Dload  Upload   Total   Spent    Left  Speed
  0     0    0     0    0     0      0      0 --:--:-- --:--:-- --:--:--     0*   Trying 127.0.0.1:8000...
* Connected to 127.0.0.1 (127.0.0.1) port 8000
> POST /api/ayesha/complete_care_v2 HTTP/1.1
> Host: 127.0.0.1:8000
> User-Agent: curl/8.6.0
> Accept: */*
> Content-Type: application/json
> Authorization: Bearer mock-token
> Content-Length: 460
> 
} [460 bytes data]
< HTTP/1.1 200 OK
< date: Fri, 30 Jan 2026 19:12:17 GMT
< server: uvicorn
< content-length: 19166
< content-type: application/json
< x-content-type-options: nosniff
< x-frame-options: DENY
< referrer-policy: strict-origin-when-cross-origin
< content-security-policy: default-src 'self'; script-src 'self' 'unsafe-inline' 'unsafe-eval'; style-src 'self' 'unsafe-inline'; img-src 'self' data: https:; font-src 'self' data:; connect-src 'self' https:; frame-ancestors 'none';
< permissions-policy: geolocation=(), microphone=(), camera=(), payment=(), usb=()
< x-xss-protection: 1; mode=block
< 
{ [19166 bytes data]
{"trials":{"trials":[],"summary":{"total_candidates":0,"hard_filtered":0,"top_results":0,"note":"Trial search unavailable - using fallback"},"provenance":{"search_method":"fallback","note":"Intent-gated ranking unavailable, using fallback","generated_at":null}},"soc_recommendation":{"regimen":"Carboplatin AUC 5-6 + Paclitaxel 175 mg/mÂ²","confidence":0.95,"rationale":"NCCN Category 1 for first-line Stage IVB HGSOC","add_ons":[{"drug":"Bevacizumab 15 mg/kg","rationale":"Ascites/peritoneal disease present â†’ bevacizumab recommended (GOG-218, ICON7)","confidence":0.9}],"evidence":["NCCN Guidelines v2024","GOG-218","ICON7"]},"ca125_intelligence":{"burden_class":"EXTENSIVE","burden_score":0.7775280682546419,"forecast":{"complete_response_target":35,"complete_response_target_unit":"U/mL","note":"Baseline CA-125 not available. General expectations: â‰¥70% drop by cycle 3, â‰¥90% by cycle 6 for chemo-sensitive disease."},"resistance_signals":[],"monitoring_strategy":{"frequency":"every_2_weeks","timing":"Until treatment initiation","rationale":"High baseline; track any changes before treatment","method":"Serum CA-125 (U/mL)"},"clinical_notes":"CA-125 of 2842.0 U/mL indicates EXTENSIVE disease burden (>1,000). CA-125 is highly trackable and suitable for response monitoring. Complete response target: <35 U/mL. Additional therapy cycles likely needed.","provenance":{"method":"ca125_intelligence_v1","data_sources":["GOG-218","ICON7","NCCN Guidelines v2024"],"thresholds":{"MINIMAL":[0,100],"MODERATE":[100,500],"SIGNIFICANT":[500,1000],"EXTENSIVE":[1000,null]},"expectations":{"cycle3_drop_percent":70,"cycle6_drop_percent":90,"complete_response_threshold":35,"resistance_threshold_percent":50},"analyzed_at":"2026-01-30T19:12:17.378850","run_id":"ca125_1769818337"}},"wiwfm":{"status":"awaiting_ngs","message":"Personalized drug efficacy predictions require tumor NGS data (somatic mutations, HRD, TMB, MSI)","ngs_fast_track":{"ctDNA":"Guardant360 - somatic BRCA/HRR, TMB, MSI (7-10 days)","tissue_HRD":"MyChoice - HRD score for PARP maintenance planning (7-14 days)","IHC":"WT1/PAX8/p53 - confirm high-grade serous histology (1-3 days)"},"confidence":null,"note":"Once NGS available, WIWFM will provide Evo2-powered S/P/E drug ranking with 70-85% confidence"},"io_selection":{"eligible":true,"eligibility_signals":["PDL1_POSITIVE_CPS"],"eligibility_quality":"inferred","needs_confirmatory_biomarkers":["tmb","msi_status","mmr_status"],"evidence_gap":"Eligibility inferred from supportive signals (PD-L1 and/or hypermutator). Confirm with measured TMB/MSI/MMR when feasible.","selected_safest":{"selected":"avelumab","brand_name":"Bavencio","target":"PD-L1","irae_risk_raw":0.13,"irae_risk_adjusted":0.13,"risk_factors":[],"monitoring_priority":["infusion_reaction","pneumonitis"],"reason":"Lowest irAE risk (13%) among options","alternatives":[{"drug":"atezolizumab","brand_name":"Tecentriq","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.14,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.06,"dermatitis":0.03},"monitoring_priority":["pneumonitis","hepatitis"],"notes":"PD-L1 may have modestly lower irAE profile","adjusted_risk":0.14,"risk_factors":[]},{"drug":"durvalumab","brand_name":"Imfinzi","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.15,"organ_specific_risks":{"pneumonitis":0.03,"hepatitis":0.02,"thyroiditis":0.07,"dermatitis":0.02},"monitoring_priority":["pneumonitis"],"notes":"Approved for lung cancer maintenance after chemoradiation","adjusted_risk":0.15,"risk_factors":[]},{"drug":"nivolumab","brand_name":"Opdivo","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.16,"organ_specific_risks":{"pneumonitis":0.03,"colitis":0.02,"hepatitis":0.03,"thyroiditis":0.08,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.02},"monitoring_priority":["pneumonitis","hepatitis","myocarditis"],"notes":"Similar to pembrolizumab, slightly different trial populations","adjusted_risk":0.16,"risk_factors":[]},{"drug":"pembrolizumab","brand_name":"Keytruda","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.17,"organ_specific_risks":{"pneumonitis":0.04,"colitis":0.02,"hepatitis":0.02,"thyroiditis":0.1,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.01},"monitoring_priority":["pneumonitis","myocarditis","thyroid"],"notes":"FDA approved for TMB-H (â‰¥10 mut/Mb) solid tumors","adjusted_risk":0.17,"risk_factors":[]},{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations.","adjusted_risk":0.35,"risk_factors":[]},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails.","adjusted_risk":0.55,"risk_factors":[]}],"avoid":[{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations.","adjusted_risk":0.35,"risk_factors":[]},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails.","adjusted_risk":0.55,"risk_factors":[]}]},"candidates":[{"drug":"avelumab","brand_name":"Bavencio","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.13,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.05},"monitoring_priority":["infusion_reaction","pneumonitis"],"notes":"Higher infusion reaction rate than other PD-L1s"},{"drug":"atezolizumab","brand_name":"Tecentriq","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.14,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.06,"dermatitis":0.03},"monitoring_priority":["pneumonitis","hepatitis"],"notes":"PD-L1 may have modestly lower irAE profile"},{"drug":"durvalumab","brand_name":"Imfinzi","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.15,"organ_specific_risks":{"pneumonitis":0.03,"hepatitis":0.02,"thyroiditis":0.07,"dermatitis":0.02},"monitoring_priority":["pneumonitis"],"notes":"Approved for lung cancer maintenance after chemoradiation"},{"drug":"nivolumab","brand_name":"Opdivo","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.16,"organ_specific_risks":{"pneumonitis":0.03,"colitis":0.02,"hepatitis":0.03,"thyroiditis":0.08,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.02},"monitoring_priority":["pneumonitis","hepatitis","myocarditis"],"notes":"Similar to pembrolizumab, slightly different trial populations"},{"drug":"pembrolizumab","brand_name":"Keytruda","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.17,"organ_specific_risks":{"pneumonitis":0.04,"colitis":0.02,"hepatitis":0.02,"thyroiditis":0.1,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.01},"monitoring_priority":["pneumonitis","myocarditis","thyroid"],"notes":"FDA approved for TMB-H (â‰¥10 mut/Mb) solid tumors"},{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations."},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails."}],"ruo_disclaimer":"Research Use Only (RUO). This is decision support, not medical advice.","provenance":{"service":"io_safest_selection_service","version":"v1"}},"food_validation":null,"supplement_recommendations":null,"resistance_playbook":null,"next_test_recommender":{"recommendations":[{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},{"test_name":"ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)","priority":2,"turnaround_days":7,"cost_estimate":"$5,000-$7,000 (typically covered by insurance)","impact_if_positive":"MSI-High/TMBâ‰¥20 â†’ IO eligible. Somatic HRR â†’ PARP confidence 90%.","impact_if_negative":"MSI-Stable/TMB<20 â†’ IO lower priority. No somatic HRR â†’ Standard care.","rationale":"MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies.","urgency":"high","test_type":"blood","ordering_info":"Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA)."}],"top_priority":{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},"total_tests":2,"high_priority_count":2,"checklist_markdown":"## ðŸ“‹ NGS Fast-Track Checklist\n\n### Priority 1: HRD Score\n- **Test**: HRD Score (MyChoice CDx or tissue-based NGS)\n- **Turnaround**: 10 days\n- **Cost**: $4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- âœ… If Positive: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n- âš ï¸ If Negative: HRD <42 â†’ PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only....\n\n**Why**: HRD score determines PARP inhibitor eligibility and confidence level....\n\n**Ordering**: Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS.\n\n---\n\n### Priority 2: ctDNA Comprehensive Panel\n- **Test**: ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)\n- **Turnaround**: 7 days\n- **Cost**: $5,000-$7,000 (typically covered by insurance)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- âœ… If Positive: MSI-High/TMBâ‰¥20 â†’ IO eligible. Somatic HRR â†’ PARP confidence 90%....\n- âš ï¸ If Negative: MSI-Stable/TMB<20 â†’ IO lower priority. No somatic HRR â†’ Standard care....\n\n**Why**: MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies....\n\n**Ordering**: Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA).\n\n---\n","provenance":{"version":"v1.1","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P1, C6) + Resistance Prophet","manager":"SR + Zo","date":"2025-01-28","note":"Includes Resistance Prophet Integration"}},"hint_tiles":{"hint_tiles":[{"category":"next_test","title":"ðŸ“‹ Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"ðŸ§ª","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"}],"total_tiles":1,"categories":["next_test"],"by_category":{"next_test":{"category":"next_test","title":"ðŸ“‹ Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"ðŸ§ª","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"}},"summary_text":"## ðŸŽ¯ Recommended Actions\n\n### ðŸ§ª ðŸ“‹ Recommended Next Test\n**Consider ordering HRD Score**\n\n**Why:**\n- HRD score determines PARP inhibitor eligibility and confidence level....\n- Turnaround: 10 days\n- Unlocks: HRD â‰¥42 â†’ PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n","provenance":{"version":"v1.0","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P5, C8)","manager":"SR","date":"2025-01-13","max_tiles":4,"tone":"suggestive","note":"Priority: Test â†’ Trials â†’ Monitor â†’ Avoid. Pre-NGS excludes 'avoid' tile."}},"mechanism_map":{"chips":[{"pathway":"DDR","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"DNA damage repair pathway burden - requires tumor NGS to assess. High burden (â‰¥70%) indicates PARP/ATR/CHK1 eligibility.","status":"awaiting_ngs"},{"pathway":"MAPK","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"RAS/RAF/MEK pathway burden - requires tumor NGS. High burden (â‰¥70%) indicates MEK/RAF inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"PI3K","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"PI3K/AKT/mTOR pathway burden - requires tumor NGS. High burden (â‰¥70%) indicates PI3K/mTOR inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"VEGF","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Angiogenesis pathway burden - requires tumor NGS. High burden (â‰¥70%) supports bevacizumab addition.","status":"awaiting_ngs"},{"pathway":"IO","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Immune checkpoint pathway - requires MSI/TMB testing. MSI-High OR TMB â‰¥20 â†’ Immunotherapy eligible.","status":"awaiting_ngs"},{"pathway":"Efflux","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Drug efflux resistance (ABCB1) - requires tumor NGS. High expression â†’ Cross-resistance to taxanes/anthracyclines.","status":"awaiting_ngs"}],"status":"awaiting_ngs","message":"Mechanism map will be available once tumor NGS results are uploaded (7-10 days). Order HRD + ctDNA to unlock.","provenance":{"mode":"pre_ngs","policy":"All chips gray per Manager C9"}},"sae_features":{"dna_repair_capacity":0.3,"pathway_burden_ddr":0.5,"pathway_burden_mapk":0.2,"pathway_burden_pi3k":0.2,"pathway_burden_vegf":0.3,"pathway_burden_her2":0.0,"io_eligible":false,"cross_resistance_risk":0.0,"essentiality_hrr_genes":0.0,"exon_disruption_score":0.0,"hotspot_mutation":false,"hotspot_details":null,"mechanism_vector":[0.5,0.2,0.2,0.3,0.0,0.0,0.0],"resistance_signals":{"resistance_detected":false,"triggers":[],"reasons":[],"policy":"2-of-3 trigger rule (MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md C7)"},"provenance":{"data_sources":{"insigh100 19626  100 19166  100   460   375k   9235 --:--:-- --:--:-- --:--:--  391k
* Connection #0 to host 127.0.0.1 left intact
ts_bundle":"Functionality, Chromatin, Essentiality, Regulatory","pathway_scores":"P from efficacy router","tumor_context":"HRD=None, TMB=0.0, MSI=Unknown","treatment_history":"0 treatments","ca125_intelligence":"Included"},"insights_bundle_values":{"functionality":0.5,"chromatin":0.5,"essentiality":0.5,"regulatory":0.5},"manager_policy":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (C1-C10)","thresholds":{"pathway_high":0.7,"pathway_moderate":0.4,"essentiality_contribution_weight":0.15,"exon_disruption_threshold":0.65,"mechanism_fit_alpha":0.7,"mechanism_fit_beta":0.3},"sae":"proxy"}},"resistance_alert":{"resistance_detected":false,"hr_restoration_suspected":false,"immediate_alert":false,"triggers_met":[],"trigger_count":0,"hrd_signal":{"triggered":false,"reason":"No baseline HRD available"},"dna_repair_signal":{"triggered":false,"reason":"No baseline DNA repair capacity available"},"ca125_signal":{"triggered":false,"reason":"CA-125 response adequate (on track)","details":{}},"recommended_actions":[],"recommended_trials":[],"timestamp":"2026-01-30T14:12:17.380712","provenance":{"detection_method":"2-of-3 trigger rule + HR restoration pattern","manager_policy":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (C7, R2)","thresholds":{"hrd_drop":15,"dna_repair_drop":0.2,"ca125_drop_cycle3":0.5,"hr_restoration_hrd_min":10,"hr_restoration_dna_repair_min":0.15},"triggers_evaluated":["hrd_drop","dna_repair_drop","ca125_inadequate"],"triggers_met":[],"trigger_count":0,"resistance_logic":"2-of-3 triggers OR HR restoration pattern"}},"resistance_prediction":null,"summary":{"components_included":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"available","confidence_level":"moderate-high (70-90%)","reasoning":"Confidence is high for guideline-based recommendations (trials, SOC, CA-125). Confidence is moderate for personalized predictions (WIWFM requires NGS)."},"provenance":{"orchestrator":"complete_care_v2_modular","for_patient":"AK (Stage IVB ovarian cancer)","endpoints_called":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"available","generated_at":"2026-01-30T19:12:17.380964","run_id":"complete_care_v2_1769818337","note":"This is NOT a demo. Real clinical decision support for Ayesha's life.","sae_phase1_enabled":true,"sae_services":["next_test_recommender","hint_tiles","mechanism_map"],"resistance_prophet_enabled":false,"resistance_prophet_phase":"phase1_retrospective_no_ca125","manager_policy_sae":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (Jan 13, 2025)","manager_policy_prophet":"MANAGER_ANSWERS_TO_RESISTANCE_PROPHET_QUESTIONS.md (Jan 14, 2025)","architecture":"modular_service_based"}}